KOMBINATION EINES FLUOR-SUBSTITUIERTEN LENVATINIB-DERIVATS UND EINES PD-1- ODER PD-L1-ANTIKÖRPERS ZUR VERWENDUNG BEI DER BEHANDLUNG EINES TUMORS

European patent · EP3939592 · In force

Register entry

Publication number
EP3939592
Application number
EP20772991
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 16, 2020
Published
Jan 19, 2022
Granted
Sep 2, 2026
Protection ends at the latest
Mar 15, 2040
Next annual fee due
Mar 31, 2027
IPC classes
A61K 31/47 (2006.01)
A61K 39/395 (2006.01)
A61K 35/00 (2006.01)
A61P 35/00 (2006.01)
A61K 45/06 (2006.01)
A61K 39/00 (2006.01)
C07K 16/28 (2006.01)
Priority
CN 201910198729 15.03.2019
PCT application
PCT/CN2020/079540 16.03.2020
PCT publication
WO2020/187188 24.09.2020
Filing language
Chinese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 2, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 02.09.2026

Parties

Holder

Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.

No.565 Tushan Road Nan'an District, Chongqing 400061, CN

Yaopharma Co., Ltd.

100 Xingguang Avenue Renhe Town Yubei District, Chongqing 401121, CN

Inventor

ZHANG, Yang

Shanghai 200131, CN

CHEN, Zhengxia

Shanghai 200131, CN

LI, Jian

Shanghai 200131, CN

CHEN, Shuhui

Shanghai 200131, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.